The mosquito-borne alphavirus, chikungunya virus (CHIKV), has recently reemerged, producing the largest epidemic ever recorded for this virus, with up to 6.5 million cases of acute and chronic rheumatic disease. There are currently no licensed vaccines for CHIKV and current anti-inflammatory drug treatment is often inadequate. Here we describe the isolation and characterization of two human monoclonal antibodies, C9 and E8, from CHIKV infected and recovered individuals. C9 was determined to be a potent virus neutralizing antibody and a biosensor antibody binding study demonstrated it recognized residues on intact CHIKV VLPs. Shotgun mutagenesis alanine scanning of 98 percent of the residues in the E1 and E2 glycoproteins of CHIKV envelope showed that the epitope bound by C9 included amino-acid 162 in the acid-sensitive region (ASR) of the CHIKV E2 glycoprotein. The ASR is critical for the rearrangement of CHIKV E2 during fusion and viral entry into host cells, and we predict that C9 prevents these events from occurring. When used prophylactically in a CHIKV mouse model, C9 completely protected against CHIKV viremia and arthritis. We also observed that when administered therapeutically at 8 or 18 hours post-CHIKV challenge, C9 gave 100\% protection in a pathogenic mouse model. Given that targeting this novel neutralizing epitope in E2 can potently protect both in vitro and in vivo, it is likely to be an important region both for future antibody and vaccine-based interventions against CHIKV.

S. Selvarajah, N. R. Sexton, K. M. Kahle, R. H. Fong, K. Mattia, J. Gardner, et al. (2013). A neutralizing monoclonal antibody targeting the acid-sensitive region in chikungunya virus E2 protects from disease. PLOS NEGLECTED TROPICAL DISEASES, 7, 1-11 [10.1371/journal.pntd.0002423].

A neutralizing monoclonal antibody targeting the acid-sensitive region in chikungunya virus E2 protects from disease.

ROSSINI, GIADA;SAMBRI, VITTORIO;
2013

Abstract

The mosquito-borne alphavirus, chikungunya virus (CHIKV), has recently reemerged, producing the largest epidemic ever recorded for this virus, with up to 6.5 million cases of acute and chronic rheumatic disease. There are currently no licensed vaccines for CHIKV and current anti-inflammatory drug treatment is often inadequate. Here we describe the isolation and characterization of two human monoclonal antibodies, C9 and E8, from CHIKV infected and recovered individuals. C9 was determined to be a potent virus neutralizing antibody and a biosensor antibody binding study demonstrated it recognized residues on intact CHIKV VLPs. Shotgun mutagenesis alanine scanning of 98 percent of the residues in the E1 and E2 glycoproteins of CHIKV envelope showed that the epitope bound by C9 included amino-acid 162 in the acid-sensitive region (ASR) of the CHIKV E2 glycoprotein. The ASR is critical for the rearrangement of CHIKV E2 during fusion and viral entry into host cells, and we predict that C9 prevents these events from occurring. When used prophylactically in a CHIKV mouse model, C9 completely protected against CHIKV viremia and arthritis. We also observed that when administered therapeutically at 8 or 18 hours post-CHIKV challenge, C9 gave 100\% protection in a pathogenic mouse model. Given that targeting this novel neutralizing epitope in E2 can potently protect both in vitro and in vivo, it is likely to be an important region both for future antibody and vaccine-based interventions against CHIKV.
2013
S. Selvarajah, N. R. Sexton, K. M. Kahle, R. H. Fong, K. Mattia, J. Gardner, et al. (2013). A neutralizing monoclonal antibody targeting the acid-sensitive region in chikungunya virus E2 protects from disease. PLOS NEGLECTED TROPICAL DISEASES, 7, 1-11 [10.1371/journal.pntd.0002423].
S. Selvarajah;N. R. Sexton;K. M. Kahle;R. H. Fong;K. Mattia;J. Gardner;K. Lu;N. M. Liss;B. Salvador;D. F. Tucker;T. Barnes;M. Mabila;X. Zhou;G. Rossini;J. B. Rucker;D. A. Sanders;A. Suhrbier;V. Sambri;A. Michault;M. O. Muench;B. J. Doranz;G. Simmons
File in questo prodotto:
File Dimensione Formato  
pntd.0002423.pdf

accesso aperto

Tipo: Versione (PDF) editoriale
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione - Condividi allo stesso modo (CCBYSA)
Dimensione 1.56 MB
Formato Adobe PDF
1.56 MB Adobe PDF Visualizza/Apri
pntd.0002423.s001.tiff

accesso aperto

Descrizione: Figure S1: Human mAbs C9 and E8 neutralization
Tipo: File Supplementare
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione (CCBY)
Dimensione 6.8 MB
Formato TIFF
6.8 MB TIFF Visualizza/Apri
pntd.0002423.s002.tiff

accesso aperto

Descrizione: Figure S2: Western blot of reduced and non-reduced CHIKV VLPs using C9 and E8 mAbs
Tipo: File Supplementare
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione (CCBY)
Dimensione 4.9 MB
Formato TIFF
4.9 MB TIFF Visualizza/Apri
pntd.0002423.s003.docx

accesso aperto

Descrizione: Text S1: Supporting methods.
Tipo: File Supplementare
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione (CCBY)
Dimensione 27.53 kB
Formato Microsoft Word XML
27.53 kB Microsoft Word XML Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/392007
Citazioni
  • ???jsp.display-item.citation.pmc??? 61
  • Scopus 87
  • ???jsp.display-item.citation.isi??? 84
social impact